Royal Jelly Facilitates Restoration of the Cognitive Ability in Trimethyltin-Intoxicated Mice
Trimethyltin (TMT) is a toxic organotin compound that induces acute neuronal death selectively in the hippocampal dentate gyrus (DG) followed by cognition impairment; however the TMT-injured hippocampal DG itself is reported to regenerate the neuronal cell layer through rapid enhancement of neurogenesis. Neural stem/progenitor cells (NS/NPCs) are present in the adult hippocampal DG, and generate neurons that can function for the cognition ability. Therefore, we investigated whether royal jelly (RJ) stimulates the regenerating processes of the TMT-injured hippocampal DG, and found that orally administered RJ significantly increased the number of DG granule cells and simultaneously improved the cognitive impairment. Furthermore, we have already shown that RJ facilitates neurogenesis of cultured NS/NPCs. These present results, taken together with previous observations, suggest that the orally administered RJ may be a promising avenue for ameliorating neuronal function by regenerating hippocampal granule cells that function in the cognition process.
Royal jelly (RJ) is a substance synthesized by the lower pharyngeal gland of the honeybee, and is thought to play important nutritional roles for the queen honeybee. RJ consists mainly of proteins, sugars, lipids, vitamins and free amino acids [1–3], and has a variety of biological activities toward various types of cells [4–7]. Earlier we reported that RJ induces neurite outgrowth from cultured PC12 cells [8, 9], a cell line of rat pheochromocytoma, via adenosine A2A receptors, and enhances the phosphorylation of both extracellular signal-regulated kinase 1 or 2 (ERK1/2) and cAMP-response element-binding protein (CREB) in both PC12 cells [9, 10] and cultured neural stem/progenitor cells (NS/NPCs) . cAMP-dependent signaling plays crucial roles in the hippocampal long-term potentiation associated with the ability for learning and memory [12, 13]. These observations suggest that RJ can activate intracellular signaling pathways by acting through adenosine A2A receptors, with the result being hippocampal long-term potentiation. However, there are no reports so far showing the effects of RJ on the recognition ability for learning and memory.
Trimethyltin (TMT) is a toxic organotin compound that induces acute neuronal death selectively in the hippocampal dentate gyrus (DG) [14–16] followed by cognition impairment [17, 18]. However, the TMT-injured hippocampal DG itself is reported to regenerate the neuronal cell layer through rapid enhancement of neurogenesis . NS/NPCs are present in the adult hippocampal DG, and they can generate neurons that can function in cognition. Furthermore, we have already shown that RJ facilitates neurogenesis of cultured NS/NPCs. Therefore, TMT-treated mice are a useful animal model to study neurogenesis in association with the ability for learning and memory.
In this study, we examined whether RJ could ameliorate TMT-induced cognitive impairment.
1. Materials and Methods
TMT was purchased from Sigma (St Louis, MO); and toluidine blue, from WALDECK-Gmbh & CoKG (Munster, Germany). RJ produced by Apis melifera (lot no T07080728R) was provided by Api Co., Ltd (Gifu, Japan). Chemical composition analysis demonstrated that the RJ used for the present study consisted of moisture (63.6%), proteins (14.5%) and 10-hydroxy-trans-2-decenoic acid (1.98%), demonstrating that a quite usual RJ was used. The RJ was lyophilized to a powder and mixed with powdered regular food (1% or 5% w/w).
1.2. Animals and Treatment of Animals
Male ICR mice (7 weeks old, 33–40 g body weight) were purchased from Japan SLC, Inc. (Shizuoka, Japan), and maintained in a controlled environment (23 ± 1°C, 55 ± 10% humidity) with a 12 h light–dark (8:00–20:00) cycle, and allowed unlimited access to food and water. The animals were cared for according to the international guidelines set out in the NIH publication Principles of Laboratory Animal Care.
The mice were divided into two groups (n = 24 each). One group was treated with a single injection of TMT (2 mg kg−1, TMT group); and the other, with an injection of phosphate-buffered saline [PBS], PBS group). Each group was subdivided into three groups fed regular food (control, n = 8 or 10) or regular food containing 1% or 5% RJ (n = 8, each) 2 days after the treatment with TMT or vehicle. There was no difference among the three groups in behavioral scores at the time of subdivision. After 6 days of consumption of the various diets the mice were subjected to behavioral tests.
1.3. Spontaneous Alternation Test in a Y-Maze
The maze was made of brown water-repellent corrugated cardboard; each arm was 40 cm long, 12 cm high, 3 cm wide at the bottom and 10 cm wide at the top. The arms converged at an equilateral triangular central area that was 4 cm at its longest axis. The procedure was basically the same as described previously . Each mouse was placed at one of the arms of the apparatus and allowed to move freely through the maze during an 8 min session. The series of arm entries was recorded. Alternation was defined as successive entry into the three arms on overlapping triplet sets. Alternation behavior (%) was calculated as the ratio of actual alternations to possible alternations (defined as the number of arm entries minus 2) multiplied by 100.
All results were expressed as the mean ± SE for each group. Simple comparisons of the means and SE of data were performed by using Student's t-test. Multiple comparisons between groups were made by one-way ANOVA, and then differences among means were analyzed by performing Tukey's test for the same number of experimental samples in a group or Holm's test for different ones in a group.
1.4. Biochemical Analyses
After the behavioral test battery, the mice were sacrificed by asphyxiation, and their brains were removed and cut in half sagittally. The hemispheres were randomly chosen from each group for each biochemical analysis, and embedded in paraffin. Serial brain sections of 8 μm in thickness including the hippocampal DG were prepared, from which five sections were selected, with one of every two consecutive sections taken. The sections were stained with neuron-specific Nissl staining using 0.5% toluidine blue solution for 25 min. They were then dehydrated, incubated in ammonia solution for 5 min, and then enclosed in resin that had been dissolved in xylene. The number of the neurons with a diameter of over 10 μm was counted without any biases in 1 mm2 areas of the DG granule cell layer.
2.1. TMT Reduced Neuronal Cell Number and Impaired Alteration Behavior Rate
To evaluate the effect of TMT on short-term memory or neuronal damage of the DG, we intraperitoneally injected a single dose of TMT into mice (2.0 mg kg−1) at day 0. TMT attenuated the spontaneous alternation behavior first on day 2, which was restored on days 3 or 5, but impaired it secondarily on day 8 (Figure 1(A)). As there was no significant difference in the number of arm entries (data not shown), mice used were suggested to have the same levels of motivation, curiosity and motor function. Namely, TMT caused both acute (day 2) and non-acute (day 8) impairments of the alternation behavior.
To clarify a link of the alternation behavioral drawback to the neuronal damage of the DG, we focused on the acute effect that occurred on experimental day 2. The brain sections from mice on day 2 were Nissl-stained, and evaluated for neuronal damage to the DG. The TMT-treated mice showed nearly a 50% marked reduction in the number of DG neurons (Figures 1(B) and 1(C)), suggesting that a half of the DG neurons were vulnerable to acute toxicity of TMT and that this neuronal loss was responsible for the impaired acute spontaneous alternation behavior (Figure 1(A)). These observations are in good agreement with those of a previous report , which suggested that neurogenesis in the DG occurs several days after TMT treatment. Therefore, the behavioral restoration found on experimental days 3 or 5 (Figure 1(A)) is likely to be a consequence of the neurogenesis spontaneously evoked in the DG. In other words, TMT might acutely induce neuronal death in the DG on day 2, and later attenuate neurogenesis in the DG around day 8. Therefore, we next evaluated the ameliorating effect of RJ on the alternation behavior and the cell number of the DG on day 8.
2.2. RJ Attenuated TMT-Induced Impairment of Spontaneous Alternation Rate and Neuronal Damage
According to the experimental schedule shown in Figure 2(a), mice were injected with TMT in PBS or PBS alone on day 0 and successively fed the RJ-containing diet for 6 days, from days 2 to 7; and the spontaneous alternation rate and neuronal cell number were then evaluated on day 8. TMT treatment significantly impaired the spontaneous alternation rate when evaluated on day 8; however, the feeding with the diet of 5% RJ, but not 1% RJ, significantly suppressed this impairment (Figure 2(c)). As there was no significant difference in the number of arm entries among the groups (Figure 2(b)), RJ did not affect the locomotion activity. After the behavioral test, the mice were fixed with 4% paraformaldehyde solution, and brain sections were prepared and stained. As shown in Figure 3(A), TMT-treated mice without the RJ diet (A, b) appeared to have a smaller number of neurons than TMT-non-treated mice without the RJ diet (A, a); whereas the TMT-treated mice with the RJ diet (A, c) appeared to have a greater number of neurons than TMT-treated ones without it. Actual cell counting demonstrated that the TMT-induced decrease in the number of neurons on day 8 (Figure 3(B), b) was significantly attenuated by RJ feeding (Figure 3(B), c).
It is known that NS/NPCs reside in the hippocampal DG of adult animals, where these cells proliferate and differentiate into neurons [20–23] in response to injury [21, 22], suggesting that the activation of NS/NPCs by some agents or substances to promote neurogenesis facilitates repair of the injured brain. Neurogenesis in the adult DG is largely responsible for regulating the number of granule cells, which cells are involved in the cognitive ability .
In this study, we aimed at evaluating if orally administered RJ could facilitate the generation of hippocampal DG granule cells invivo. TMT is reported to induce acute neuronal death selectively in the DG [14–16], but the neurons substantially regenerate in several days, suggesting that TMT-treated mice are useful as an invivo model to study neurogenesis . Ogita et al.  demonstrated that the administration of TMT induced acute neuronal death in the DG selectively 2 days later and that 5-bromo--deoxyuridine (BrdU) incorporation into the DG cells was facilitated at an early stage (days 2–5) after the damage by TMT treatment. The BrdU-positive cells were also positive for nestin, NeuroD3, doublecortin or NeuN, suggesting that they were neural progenitor cells or neuronal precursors. From these results, they concluded that the hippocampal DG itself is capable of regenerating the neuronal cell layer through rapid enhancement of neurogenesis after TMT-induced injury.
Therefore, we investigated the effect of RJ on the neurogenesis of the DG using this animal model. We found that the oral administration of RJ for 6 days could significantly increase the number of Nissl-stained cells in the TMT-damaged DG on experimental day 8 when the TMT-induced neurogenesis would have ceased (Figure 3). It is conceivable that these generated neurons were functional, because RJ simultaneously ameliorated the cognitive impairment (Figure 2).
Our recent results highlighted a novel property of RJ, that is, that it facilitates the differentiation of all types of brain cells including neurons from cultured NS/NPCs , suggesting that RJ contains plural components that differently influence neuronal and/or glial lineages. Therefore, it might be expected that RJ or its components would facilitate invivo neurogenesis in the hippocampal DG. In fact, adenosine monophosphate (AMP) N1-oxide, which we earlier we identified to be a neurotrophic component of RJ , facilitates the generation of astrocytes from NS/PCs through activation of STAT3 . On the other hand, 10-hydroxy-trans-2-decenoic acid, an unsaturated fatty acid characteristic of RJ, increases the generation of neurons and decreases that of astrocytes and oligodendrocytes from NSCs , suggesting that this compound unique to RJ is a predominant contributor to the neurogenesis.
Based on the results of the present study, we propose that RJ can facilitate neurogenesis invivo, which suggests that RJ may serve a tool for protection against and therapy for some particular neurological disorders such as depression, whose etiology is associated with reduced hippocampal DG neurogenesis . RJ has the potential of being a promising evidence-based complementary and alternative medicine.
H. Izuta, Y. Chikaraishi, M. Shimazawa, S. Mishima, and H. Hara, “10-hydroxy-2-decenoic acid, a major fatty acid from RJ, inhibits VEGF-induced angiogenesis in human umbilical vein endothelial cells,” in Evidence-Based Complementary and Alternative Medicine, vol. 6, no. 4, pp. 489–494, 2009.View at: Publisher Site | Google Scholar
T. Takenaka, “Chemical compositions of royal jelly,” Honeybee Science, vol. 3, pp. 69–74, 1982.View at: Google Scholar
T. Echigo, T. Takenaka, and K. Yatsunami, “Comparative studies on chemical composition of honey, royal jelly and pollen loads,” Bulletin of the Faculty of Agriculture Tamagawa University, vol. 26, pp. 1–12, 1986.View at: Google Scholar
A. Fujii, S. Kobayashi, and S. Kobayashi, “Augmentation of wound healing by royal jelly (RJ) in streptozotocin-diabetic rats,” Japanese Journal of Pharmacology, vol. 53, no. 3, pp. 331–337, 1990.View at: Google Scholar
H. Oka, Y. Emori, N. Kobayashi, Y. Hayashi, and K. Nomoto, “Suppression of allergic reactions by royal jelly in association with the restoration of macrophage function and the improvement of Th1/Th2 cell responses,” International Immunopharmacology, vol. 1, no. 3, pp. 521–532, 2001.View at: Publisher Site | Google Scholar
L. Šver, N. Oršolić, Z. Tadić, B. Njari, I. Valpotić, and I. Bašić, “A royal jelly as a new potential immunomodulator in rats and mice,” Comparative Immunology, Microbiology and Infectious Diseases, vol. 19, no. 1, pp. 31–38, 1996.View at: Publisher Site | Google Scholar
Y. Taniguchi, K. Kohno, and K. Kohno, “Oral administration of royal jelly inhibits the development of atopic dermatitis-like skin lesions in NC/Nga mice,” International Immunopharmacology, vol. 3, no. 9, pp. 1313–1324, 2003.View at: Publisher Site | Google Scholar
N. Hattori, H. Nomoto, S. Mishima, S. Inagaki, M. Goto, M. Sako, and S. Furukawa, “Identification of AMP -oxide in royal jelly as a component neurotrophic toward cultured rat pheochromocytoma PC12 cells,” Bioscience, Biotechnology and Biochemistry, vol. 70, no. 4, pp. 897–906, 2006.View at: Publisher Site | Google Scholar
N. Hattori, H. Nomoto, H. Fukumitsu, S. Mishima, and S. Furukawa, “Royal jelly-induced neurite outgrowth from rat pheochromocytoma PC12 cells requires integrin signal independent of activation of extracellular signal-regulated kinases,” Biomedical Research, vol. 28, no. 3, pp. 139–146, 2007.View at: Publisher Site | Google Scholar
N. Hattori, H. Nomoto, H. Fukumitsu, S. Mishima, and S. Furukawa, “Royal jelly and its unique fatty acid, 10-hydroxy-trans-2-decenoic acid, promote neurogenesis by neural stem/progenitor cells in vitro,” Biomedical Research, vol. 28, no. 5, pp. 261–266, 2007.View at: Publisher Site | Google Scholar
N. Hattori, H. Nomoto, H. Fukumitsu, S. Mishima, and S. Furukawa, “AMP -oxide, a unique compound of royal jelly, induces neurite outgrowth from PC12 cells via signaling by protein kinase A independent of that by mitogen-activated protein kinase,” in Evidence-Based Complementary and Alternative Medicine, vol. 7, no. 1, pp. 63–68, 2010.View at: Publisher Site | Google Scholar
T. Abel, P. V. Nguyen, M. Barad, T. A. S. Deuel, E. R. Kandel, and R. Bourtchouladze, “Genetic demonstration of a role for PKA in the late phase of LTP and in hippocampus-based long-term memory,” Cell, vol. 88, no. 5, pp. 615–626, 1997.View at: Publisher Site | Google Scholar
U. Frey, Y.-Y. Huang, and E. R. Kandel, “Effects of cAMP simulate a late stage of LTP in hippocampal CA1 neurons,” Science, vol. 260, no. 5114, pp. 1661–1664, 1993.View at: Google Scholar
A. Fiedorowicz, I. Figiel, B. Kamińska, M. Zaremba, S. Wilk, and B. Oderfeld-Nowak, “Dentate granule neuron apoptosis and glia activation in murine hippocampus induced by trimethyltin exposure,” Brain Research, vol. 912, no. 2, pp. 116–127, 2001.View at: Publisher Site | Google Scholar
K. Ogita, Y. Nitta, M. Watanabe, Y. Nakatani, N. Nishiyama, C. Sugiyama, and Y. Yoneda, “In vivo activation of c-Jun N-terminal kinase signaling cascade prior to granule cell death induced by trimethyltin in the dentate gyrus of mice,” Neuropharmacology, vol. 47, no. 4, pp. 619–630, 2004.View at: Publisher Site | Google Scholar
K. Ogita, N. Nishiyama, C. Sugiyama, K. Higuchi, M. Yoneyama, and Y. Yoneda, “Regeneration of granule neurons after lesioning of hippocampal dentate gyrus: evaluation using adult mice treated with trimethyltin chloride as a model,” Journal of Neuroscience Research, vol. 82, pp. 609–621, 2005.View at: Google Scholar
M. Niittykoski, R. Lappalainen, J. Jolkkonen, A. Haapalinna, P. Riekkinen Sr., and J. Sirvio, “Systemic administration of atipamezole, a selective antagonist of alpha-2 adrenoceptors, facilitates behavioural activity but does not influence short-term or long-term memory in trimethyltin-intoxicated and control rats,” Neuroscience & Biobehavioral Reviews, vol. 22, pp. 735–750, 1998.View at: Google Scholar
N. Ishida, M. Akaike, S. Tsutsumi et al., “Trimethyltin syndrome as a hippocampal degeneration model: temporal changes and neurochemical features of seizure susceptibility and learning impairment,” Neuroscience, vol. 81, pp. 1183–1191, 1997.View at: Google Scholar
K. Yamada, T. Tanaka, L. B. Zou et al., “Long-term deprivation of estrogens by ovariectomy potentiates beta-amyloyd-induced working memory deficits in rats,” British Journal of Pharmacology, vol. 128, pp. 419–427, 1999.View at: Google Scholar
F. H. Gage, “Mammalian neural stem cells,” Science, vol. 287, no. 5457, pp. 1433–1438, 2000.View at: Publisher Site | Google Scholar
C. M. Morshead, C. G. Craig, and D. Van der Kooy, “In vivo clonal analyses reveal the properties of endogenous neural stem cell proliferation in the adult mammalian forebrain,” Development, vol. 125, no. 12, pp. 2251–2261, 1998.View at: Google Scholar
C. Lois and A. Alvarez-Buylla, “Long-distance neuronal migration in the adult mammalian brain,” Science, vol. 264, no. 5162, pp. 1145–1148, 1994.View at: Google Scholar
M. B. Luskin, “Neuronal cell lineage in the vertebrate central nervous system,” FASEB Journal, vol. 8, no. 10, pp. 722–730, 1994.View at: Google Scholar
E. Gould, P. Tanapat, N. B. Hastings, and T. J. Shors, “Neurogenesis in adulthood: a possible role in learning,” Trends in Cognitive Sciences, vol. 3, pp. 186–192, 1999.View at: Google Scholar
N. Hattori, H. Nomoto, H. Fukumitsu, S. Mishima, and S. Furukawa, “AMP -oxide potentiates astrogenesis by cultured neural stem/progenitor cells through STAT3 activation,” Biomedical Research, vol. 28, no. 6, pp. 295–299, 2007.View at: Publisher Site | Google Scholar
D. T. Balu and I. Lucki, “Adult hippocampal neurogenesis: regulation, functional implications, and contribution to disease pathology,” Neuroscience and Biobehavioral Reviews, vol. 33, no. 3, pp. 232–252, 2009.View at: Publisher Site | Google Scholar